Dermatologic symptoms associated with the multikinase inhibitor sorafenib - 08/08/11
, Christina Mateus, MD a, Alain Spatz, MD b, Janine Wechsler, MD d, Bernard Escudier, MD c
Reprint requests: Caroline Robert, MD, PhD, Dermatology Unit, Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94800 Villejuif, France.Abstract |
Background |
The multikinase inhibitor sorafenib (Nexavar) is associated with a relatively high incidence of dermatologic symptoms.
Objective |
We sought to evaluate and provide guidance on the diagnosis and clinical management of dermatologic symptoms associated with sorafenib in patients with advanced solid tumors.
Methods |
English-language studies representative of a patient population with a variety of tumor types, who received single-agent sorafenib, were selected. Particular emphasis was placed on the phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGETs).
Results |
Frequently observed dermatologic side effects (any grade in TARGETs) of sorafenib include rash/desquamation (40%), hand–foot skin reaction (30%), alopecia (27%), and pruritus (19%). Generally, dermatologic symptoms resolve with appropriate management, including topical treatments, dose interruptions, dose reductions, or a combination of these.
Limitations |
The results presented here are based on a limited number of studies.
Conclusion |
Although sorafenib is associated with dermatologic symptoms, these are usually resolved with appropriate intervention, patient-led practical treatment, and preventative measures.
Le texte complet de cet article est disponible en PDF.Abbreviations used : bid, CK, HFSR, TARGETs, VEGFR
Plan
| Funding sources: None. |
|
| Disclosure: Dr Robert has received honoraria from Bayer. Dr Escudier is an investigator for Bayer, Roche, and Wyeth, and has received honoraria from each of these companies. Drs Mateus, Spatz, and Wechsler have no conflicts of interest to declare. |
Vol 60 - N° 2
P. 299-305 - février 2009 Retour au numéro
Article précédent
- Dental manifestations of dermatologic conditions
- Anatoli Freiman, Daniel Borsuk, Benjamin Barankin, Geoffrey H. Sperber, Bernice Krafchik
- Dengue fever
- Warren R. Heymann
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?